139 related articles for article (PubMed ID: 38348690)
1. The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring
Kim DW; Schram AM; Hollebecque A; Nishino K; Macarulla T; Rha SY; Duruisseaux M; Liu SV; Al Hallak MN; Umemoto K; Wesseler C; Cleary JM; Springfeld C; Neuzillet C; Joe A; Jauhari S; Ford J; Goto K
Future Oncol; 2024 Feb; ():. PubMed ID: 38348690
[TBL] [Abstract][Full Text] [Related]
2. Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.
Schram AM; Odintsov I; Espinosa-Cotton M; Khodos I; Sisso WJ; Mattar MS; Lui AJW; Vojnic M; Shameem SH; Chauhan T; Torrisi J; Ford J; O'Connor MN; Geuijen CAW; Schackmann RCJ; Lammerts van Bueren JJ; Wasserman E; de Stanchina E; O'Reilly EM; Ladanyi M; Drilon A; Somwar R
Cancer Discov; 2022 May; 12(5):1233-1247. PubMed ID: 35135829
[TBL] [Abstract][Full Text] [Related]
3. Zenocutuzumab Shines in PDAC.
Cancer Discov; 2021 Aug; 11(8):1864. PubMed ID: 34112697
[TBL] [Abstract][Full Text] [Related]
4. A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors.
Gan HK; Millward M; Jalving M; Garrido-Laguna I; Lickliter JD; Schellens JHM; Lolkema MP; Van Herpen CLM; Hug B; Tang L; O'Connor-Semmes R; Gagnon R; Ellis C; Ganji G; Matheny C; Drilon A
Oncologist; 2021 Oct; 26(10):e1844-e1853. PubMed ID: 34132450
[TBL] [Abstract][Full Text] [Related]
5. NRG1 fusions: Biology to therapy.
Liu SV
Lung Cancer; 2021 Aug; 158():25-28. PubMed ID: 34098222
[TBL] [Abstract][Full Text] [Related]
6.
Jones MR; Williamson LM; Topham JT; Lee MKC; Goytain A; Ho J; Denroche RE; Jang G; Pleasance E; Shen Y; Karasinska JM; McGhie JP; Gill S; Lim HJ; Moore MJ; Wong HL; Ng T; Yip S; Zhang W; Sadeghi S; Reisle C; Mungall AJ; Mungall KL; Moore RA; Ma Y; Knox JJ; Gallinger S; Laskin J; Marra MA; Schaeffer DF; Jones SJM; Renouf DJ
Clin Cancer Res; 2019 Aug; 25(15):4674-4681. PubMed ID: 31068372
[TBL] [Abstract][Full Text] [Related]
7. The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic
Odintsov I; Lui AJW; Sisso WJ; Gladstone E; Liu Z; Delasos L; Kurth RI; Sisso EM; Vojnic M; Khodos I; Mattar MS; de Stanchina E; Leland SM; Ladanyi M; Somwar R
Clin Cancer Res; 2021 Jun; 27(11):3154-3166. PubMed ID: 33824166
[TBL] [Abstract][Full Text] [Related]
8. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.
Laskin J; Liu SV; Tolba K; Heining C; Schlenk RF; Cheema P; Cadranel J; Jones MR; Drilon A; Cseh A; Gyorffy S; Solca F; Duruisseaux M
Ann Oncol; 2020 Dec; 31(12):1693-1703. PubMed ID: 32916265
[TBL] [Abstract][Full Text] [Related]
9. Detection of NRG1 Gene Fusions in Solid Tumors.
Jonna S; Feldman RA; Swensen J; Gatalica Z; Korn WM; Borghaei H; Ma PC; Nieva JJ; Spira AI; Vanderwalde AM; Wozniak AJ; Kim ES; Liu SV
Clin Cancer Res; 2019 Aug; 25(16):4966-4972. PubMed ID: 30988082
[TBL] [Abstract][Full Text] [Related]
10. RNA Sequencing Identifies Novel NRG1 Fusions in Solid Tumors that Lack Co-Occurring Oncogenic Drivers.
Severson E; Achyut BR; Nesline M; Pabla S; Previs RA; Kannan G; Chenn A; Zhang S; Klein R; Conroy J; Sausen M; Sathyan P; Saini KS; Ghosh A; Jensen TJ; Reddy P; Ramkissoon SH
J Mol Diagn; 2023 Jul; 25(7):454-466. PubMed ID: 37164276
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.
Cadranel J; Liu SV; Duruisseaux M; Branden E; Goto Y; Weinberg BA; Heining C; Schlenk RF; Cheema P; Jones MR; Drilon A; Trombetta D; Muscarella LA; Tolba K; Gounant V; Cseh A; Solca F; Laskin JJ; Renouf DJ
Oncologist; 2021 Jan; 26(1):7-16. PubMed ID: 32852072
[TBL] [Abstract][Full Text] [Related]
12. Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.
Jones MR; Lim H; Shen Y; Pleasance E; Ch'ng C; Reisle C; Leelakumari S; Zhao C; Yip S; Ho J; Zhong E; Ng T; Ionescu D; Schaeffer DF; Mungall AJ; Mungall KL; Zhao Y; Moore RA; Ma Y; Chia S; Ho C; Renouf DJ; Gelmon K; Jones SJM; Marra MA; Laskin J
Ann Oncol; 2017 Dec; 28(12):3092-3097. PubMed ID: 28950338
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic Neuregulin 1 gene (NRG1) fusions in cancer: A potential new therapeutic opportunities.
Zhang C; Mei W; Zeng C
Biochim Biophys Acta Rev Cancer; 2022 May; 1877(3):188707. PubMed ID: 35247506
[TBL] [Abstract][Full Text] [Related]
14. Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report.
Nie X; Zhang P; Bie Z; Song C; Zhang M; Ma D; Cui D; Cheng G; Li H; Lei Y; Su X; Wu W; Li L
World J Surg Oncol; 2023 Aug; 21(1):246. PubMed ID: 37587479
[TBL] [Abstract][Full Text] [Related]
15. NRG1 and NRG2 fusions in non-small cell lung cancer (NSCLC): seven years between lights and shadows.
Trombetta D; Sparaneo A; Fabrizio FP; Di Micco CM; Rossi A; Muscarella LA
Expert Opin Ther Targets; 2021 Oct; 25(10):865-875. PubMed ID: 34706602
[TBL] [Abstract][Full Text] [Related]
16. Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population.
Pan Y; Zhang Y; Ye T; Zhao Y; Gao Z; Yuan H; Zheng D; Zheng S; Li H; Li Y; Jin Y; Sun Y; Chen H
J Thorac Oncol; 2019 Nov; 14(11):2003-2008. PubMed ID: 31382039
[TBL] [Abstract][Full Text] [Related]
17. NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis.
Nagasaka M; Ou SI
Trends Cancer; 2022 Mar; 8(3):242-258. PubMed ID: 34996744
[TBL] [Abstract][Full Text] [Related]
18. Successful targeting of the
Wu X; Zhang D; Shi M; Wang F; Li Y; Lin Q
Ann Transl Med; 2021 Oct; 9(19):1507. PubMed ID: 34805369
[TBL] [Abstract][Full Text] [Related]
19. Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers.
Odintsov I; Mattar MS; Lui AJW; Offin M; Kurzatkowski C; Delasos L; Khodos I; Asher M; Daly RM; Rekhtman N; de Stanchina E; Ganji G; Ladanyi M; Somwar R
J Thorac Oncol; 2021 Jul; 16(7):1149-1165. PubMed ID: 33839363
[TBL] [Abstract][Full Text] [Related]
20. NRG1 fusions in breast cancer.
Howarth KD; Mirza T; Cooke SL; Chin SF; Pole JC; Turro E; Eldridge MD; Garcia RM; Rueda OM; Boursnell C; Abraham JE; Caldas C; Edwards PAW
Breast Cancer Res; 2021 Jan; 23(1):3. PubMed ID: 33413557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]